NEW YORK, May 27 (Reuters) - Drugmakers are renewing efforts
to develop medicines to fight emerging antibiotic-resistant
bacteria, but creating new classes of drugs on the scale needed
is unlikely to happen without new financial incentives to make
the effort worth the investment, companies and industry experts
said.
Read more
No comments:
Post a Comment